FDA Issues Warning Letter to Merck KGaA’s API Plant in Switzerland

The U.S. Food and Drug Administration (FDA) issued a warning letter in December 2011, to the active pharmaceutical ingredient (API) facility at Corsier-sur-Vevey, Switzerland, of Merck KGaA’s Merck Serono (Geneva) division, for deviating from current good manufacturing practice (cGMP). The FDA published the warning letter on its website, earlier this month. An FDA inspection of the Corsier-sur-Vevey API facility from June 1-June 9, 2011, identified significant deviations from cGMP for the manufacture of APIs and significant violations to requirements...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers